Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance

Crispr Therapeutics AGTrade
Cognizant Technology Solutions CorpTrade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Cognizant Technology Solutions Corp — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Cognizant Technology Solutions Corp trades at $57.62 (market cap $26.40B). The key difference: Cognizant Technology Solutions Corp is far larger — about 5× Crispr Therapeutics AG's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.

CRSPCTSH
Market Cap
$5.23B$26.40B
Sector
HealthTechnology
52-Week High
$76.78$86.70
52-Week Low
$44.34$38.73
Enterprise Value
$3.65B$27.44B
Dividend Yield
2.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

Cognizant Technology Solutions Corp

CTSH trades at $57.76, down 0.94% on the day, with a bullish technical signal and strong cash flow generation. Recent Q2 2026 earnings missed estimates, but revenue beat, and the company maintains solid profitability with a 10.26% net margin. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience in financial services growth amid AI investments.

The outlook remains cautiously optimistic with upside potential from AI initiatives and large-deal execution, though risks include client spending caution and competitive pressures. Valuation metrics like a P/E of 12.58 suggest room for growth if earnings momentum improves.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Cognizant Technology Solutions Corp

Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.

Read more on CTSH